W. Paul Glezen

W. Paul Glezen

Auto-generated profile, based on publicly available information

W. Paul Glezen

Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2006 in Journal of Clinical Virology
Verified
Journal Article
Closed access
WGW. Paul Glezen
W. Paul Glezen

1 December 2010 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
WGW. Paul Glezen
W. Paul Glezen
MGManjusha J. Gaglani
Manjusha J. Gaglani
CKClaudia A. Kozinetz
Claudia A. Kozinetz
PPPedro A. Piedra
Pedro A. Piedra
Background. Influenza is an uncontrolled epidemic disease that is vaccine preventable. New recommendations for universal immunization present a chall

11 December 2008 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
WGW. Paul Glezen
W. Paul Glezen
This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they exist. The article ends with the author's clinical recommendations.

1 December 2006 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
WGW. Paul Glezen
W. Paul Glezen

20 December 2005 in International Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
WGW Paul Glezen
W Paul Glezen
LSLone Simonsen
Lone Simonsen
During the period from 1989 to 1997 the vaccination rate for elderly persons ≥65 years of age in the US increased from 30 to 67%. Despite this increase in coverage, mortality and hospitalization rates continued to increase rather than decline as would be expected if the vaccine were optimally efficacious. Currently over 50 000 deaths result from influenza virus infections each year in the US.1 The rate of hospitalizations owing to complications of influenza has increased steadily since 1979 and the average number for the last decade is almost 400 000 per year.2 About 85% of deaths and 63% of hospitalizations attributable to influenza occur in persons ≥65 years of age. About two-thirds of the US elderly have been vaccinated each year since 1997. Despite substantial vaccine coverage in the most vulnerable group, no effect on national all-cause excess mortality or hospitalizations has been evident—even after taking population aging and changing virus dominance patterns into account.3 Furthermore, observational studies of large cohorts have reported that elderly persons who elect to take the influenza vaccine were less likely to die or to be hospitalized during the influenza season than were unvaccinated elderly.4 Protection rates were estimated at 47% for all wintertime deaths and 22–27% for hospitalization. The investigators noted that the elderly who chose to be vaccinated had more co-morbidities, like diabetes or cardiopulmonary diseases, listed on their administrative data files and were, therefore, considered to be at greater risk for complications of influenza than their unvaccinated cohorts. The apparent 50% reduction in mortality is remarkable because the wintertime excess all-cause mortality that might be attributed to influenza was found to be <10% of total wintertime deaths.1,3 The finding that influenza vaccine protection in these observational studies exceeded any possible expectation requires some explanation.

1 October 2008 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
WGW Paul Glezen
W Paul Glezen
WPW Paul
W Paul
Influenza is an uncontrolled epidemic disease that is vaccine preventable. Each winter the peak of medically attended acute respiratory illness coincides with the peak of influenza virus activity. The anatomy of an urban influenza epidemic is presented highlighting the role of children in the spread of influenza. The efficacy and safety of the live attenuated influenza vaccine (LAIV) for children are documented and the indirect effectiveness (herd protection) of vaccinating schoolchildren is demonstrated. Children have the highest attack rates during influenza epidemics and the consequences of influenza virus infection can be severe regardless of the virus type—A(H1N1), A(H3N2), or B. Early in the epidemic, over one-half of the culture-positive illnesses will occur in school-aged children demonstrating their role in spreading the virus in the community. LAIV has been shown to be superior to inactivated vaccine for children and is safe even for children with mild intermittent asthma. One dose of LAIV is effective and gives almost immediate protection. LAIV administered by nasal spray is readily accepted by children. Several studies have demonstrated herd protection by immunizing schoolchildren. These studies have shown that immunizing schoolchildren is more efficient than vaccinating elderly and high-risk patients directly. Current recommendations for influenza vaccine give priority to more than 200 million persons in the United States, but vaccine coverage has not improved since 1997. Systematic delivery of influenza vaccine in school-based and workplace-based clinics would greatly enhance the control of epidemic influenza and help prepare for the next pandemic.